Udo Polzer

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Ludwig Kappos, Amit Bar‐Or, Bruce Cree et al. · The Lancet · 2018 · 896 citations

Neurological Disorder, Clinical Neurology, Clinical Trials +9

Facial affect recognition in the course of schizophrenia

Wolfgang Wölwer, Marcus R. Streit, W. Gaebel et al. · European Archives of Psychiatry and Clinical Neuroscience · 1996 · 123 citations

Psychopathology, Facial Expression Recognition, Psychiatry +10

Fatigue, sleepiness, and physical activity in patients with multiple sclerosis

S. Merkelbach, Hartmut Schulz, Hans Wolfgang Kölmel et al. · Journal of Neurology · 2010 · 59 citations

Sleep, Physical Activity, Sleep Disorder +9

Influence of the Nonergot Dopamine Agonist Piribedil on Vigilance in Patients With Parkinson Disease and Excessive Daytime Sleepiness (PiViCog-PD)

Karla Eggert, Christian Öhlwein, Jan Kassubek et al. · Clinical Neuropharmacology · 2014 · 36 citations

Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting

María Trojano, Helmut Butzkueven, Ludwig Kappos et al. · Multiple Sclerosis and Related Disorders · 2018 · 18 citations · Full text